Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania
The World Health Organization recommends artemisinin-based combination (ACT) for the treatment of uncomplicated malaria. Post-licensure safety data on newly registered ACT is critical for evaluating their risk/benefit profile in malaria endemic countries. The clinical safety of the newly registered...
Gespeichert in:
| Veröffentlicht in: | Malaria journal 2015-04, Vol.14 (1), p.160, Article 160 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 160 |
| container_title | Malaria journal |
| container_volume | 14 |
| creator | Baiden, Rita Oduro, Abraham Halidou, Tinto Gyapong, Margaret Sie, Ali Macete, Eusebio Abdulla, Salim Owusu-Agyei, Seth Mulokozi, Abdunoor Adjei, Alex Sevene, Esperanca Compaoré, Guillaume Valea, Innocent Osei, Isaac Yawson, Abena Adjuik, Martin Akparibo, Raymond Ogutu, Bernhards Upunda, Gabriel Leonard Smith, Peter Binka, Fred |
| description | The World Health Organization recommends artemisinin-based combination (ACT) for the treatment of uncomplicated malaria. Post-licensure safety data on newly registered ACT is critical for evaluating their risk/benefit profile in malaria endemic countries. The clinical safety of the newly registered combination, Eurartesim®, following its introduction into the public health system in four African countries was assessed.
This was a prospective, observational, open-label, non-comparative, longitudinal, multi-centre study using cohort event monitoring. Patients with confirmed malaria had their first dose observed and instructed on how to take the second and the third doses at home. Patients were contacted on day 5 ± 2 to assess adherence and adverse events (AEs). Spontaneous reporting of AEs was continued till day 28. A nested cohort who completed full treatment course had repeated electrocardiogram (ECG) measurements to assess effect on QTc interval.
A total of 10,925 uncomplicated malaria patients were treated with Eurartesim®. Most patients,95% (10,359/10,925), did not report any adverse event following at least one dose of Eurartesim®. A total of 797 adverse events were reported. The most frequently reported, by system organ classification, were infections and infestations (3. 24%) and gastrointestinal disorders (1. 37%). In the nested cohort, no patient had QTcF > 500 ms prior to day 3 pre-dose 3. Three patients had QTcF > 500 ms (509 ms, 501 ms, 538 ms) three to four hours after intake of the last dose. All the QTcF values in the three patients had returned to |
| doi_str_mv | 10.1186/s12936-015-0664-9 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4405867</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A541473859</galeid><sourcerecordid>A541473859</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-b3750e9eda258f44c5de958a6837bd6c3f66af441ca2b5532c58ac5ff72ef1593</originalsourceid><addsrcrecordid>eNptUsFu1DAQjRCIlsIHcEGWuIC0aeMkdrIXpFK1BakIDuVsTexxY8jaqe2s2H4UH8Hv8BM4u1BtJeSDrZn33oxnXpa9pMUxpS0_CbRcVjwvKMsLzut8-Sg7pHXD8rJt2OO990H2LIRvRUGbtimfZgcla1uWzmH2-4t3YUQZzRqJ6wL6NUTjLAwkxEltSHQE1zBMEJHEHokcjDVyToPGuCFOb8Pa_ECVKxeQgI-4MiHBbN5BQEWkW3XGbnXJ-eRnQDCrXz_JG2X6jfJuj3IymhE93E7G4tsFMZaMUzcYSXqEIfZEgzSDiQbDnHs_-e9JmVxAcAvyyd1BqnQ74YJc9mBhQcAqcg32DqyB59kTDUPAF3_vo-zrxfn12Yf86vPlx7PTq1zWnMe8qxpW4BIVpDHpupZM4ZK1wNuq6RSXleYcUpxKKDvGqlKmpGRaNyVqypbVUfZup5s6X6GSaKOHQYzerMBvhAMjHmas6cWNW4u6LljLmyTweidwAwMKY7VLMJkGJMUpq9NWq3Zb5vg_qHRUmqV0FrVJ8QcEuiPItPPgUd-3RAsxG0rsDCWSocRsKDFzXu3_5Z7xz0HVH4mVzvo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><creator>Baiden, Rita ; Oduro, Abraham ; Halidou, Tinto ; Gyapong, Margaret ; Sie, Ali ; Macete, Eusebio ; Abdulla, Salim ; Owusu-Agyei, Seth ; Mulokozi, Abdunoor ; Adjei, Alex ; Sevene, Esperanca ; Compaoré, Guillaume ; Valea, Innocent ; Osei, Isaac ; Yawson, Abena ; Adjuik, Martin ; Akparibo, Raymond ; Ogutu, Bernhards ; Upunda, Gabriel Leonard ; Smith, Peter ; Binka, Fred</creator><creatorcontrib>Baiden, Rita ; Oduro, Abraham ; Halidou, Tinto ; Gyapong, Margaret ; Sie, Ali ; Macete, Eusebio ; Abdulla, Salim ; Owusu-Agyei, Seth ; Mulokozi, Abdunoor ; Adjei, Alex ; Sevene, Esperanca ; Compaoré, Guillaume ; Valea, Innocent ; Osei, Isaac ; Yawson, Abena ; Adjuik, Martin ; Akparibo, Raymond ; Ogutu, Bernhards ; Upunda, Gabriel Leonard ; Smith, Peter ; Binka, Fred</creatorcontrib><description>The World Health Organization recommends artemisinin-based combination (ACT) for the treatment of uncomplicated malaria. Post-licensure safety data on newly registered ACT is critical for evaluating their risk/benefit profile in malaria endemic countries. The clinical safety of the newly registered combination, Eurartesim®, following its introduction into the public health system in four African countries was assessed.
This was a prospective, observational, open-label, non-comparative, longitudinal, multi-centre study using cohort event monitoring. Patients with confirmed malaria had their first dose observed and instructed on how to take the second and the third doses at home. Patients were contacted on day 5 ± 2 to assess adherence and adverse events (AEs). Spontaneous reporting of AEs was continued till day 28. A nested cohort who completed full treatment course had repeated electrocardiogram (ECG) measurements to assess effect on QTc interval.
A total of 10,925 uncomplicated malaria patients were treated with Eurartesim®. Most patients,95% (10,359/10,925), did not report any adverse event following at least one dose of Eurartesim®. A total of 797 adverse events were reported. The most frequently reported, by system organ classification, were infections and infestations (3. 24%) and gastrointestinal disorders (1. 37%). In the nested cohort, no patient had QTcF > 500 ms prior to day 3 pre-dose 3. Three patients had QTcF > 500 ms (509 ms, 501 ms, 538 ms) three to four hours after intake of the last dose. All the QTcF values in the three patients had returned to <500 ms at the next scheduled ECG on day 7 (470 ms, 442 ms, 411 ms). On day 3 pre- and post-dose 3, 70 and 89 patients, respectively, had a QTcF increase of ≥ 60 ms compared to their baseline, but returned to nearly baseline values on day 7.
Eurartesim® single course treatment for uncomplicated falciparum malaria is well-tolerated. QT interval prolongation above 500 ms may occur at a rate of three per 1,002 patients after the third dose with no association of any clinical symptoms. QT interval prolongation above 60 ms was detected in less than 10% of the patients without any clinical abnormalities.</description><identifier>ISSN: 1475-2875</identifier><identifier>EISSN: 1475-2875</identifier><identifier>DOI: 10.1186/s12936-015-0664-9</identifier><identifier>PMID: 25885858</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adolescent ; Adult ; Africa ; Aged ; Aged, 80 and over ; Antimalarials - administration & dosage ; Antimalarials - adverse effects ; Artemisinins - administration & dosage ; Artemisinins - adverse effects ; Care and treatment ; Child ; Child, Preschool ; Cohort Studies ; Comparative analysis ; Control ; Drug Combinations ; Drug therapy ; Drug-Related Side Effects and Adverse Reactions - epidemiology ; Drug-Related Side Effects and Adverse Reactions - pathology ; Female ; Gastrointestinal diseases ; Health aspects ; Health Facilities ; Heart Conduction System - drug effects ; Humans ; Infant ; Infant, Newborn ; Longitudinal Studies ; Malaria ; Malaria - drug therapy ; Male ; Medical research ; Medicine, Experimental ; Middle Aged ; Prospective Studies ; Quinolines - administration & dosage ; Quinolines - adverse effects ; Safety and security measures ; Young Adult</subject><ispartof>Malaria journal, 2015-04, Vol.14 (1), p.160, Article 160</ispartof><rights>COPYRIGHT 2015 BioMed Central Ltd.</rights><rights>Baiden et al.; licensee BioMed Central. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-b3750e9eda258f44c5de958a6837bd6c3f66af441ca2b5532c58ac5ff72ef1593</citedby><cites>FETCH-LOGICAL-c466t-b3750e9eda258f44c5de958a6837bd6c3f66af441ca2b5532c58ac5ff72ef1593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405867/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405867/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25885858$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baiden, Rita</creatorcontrib><creatorcontrib>Oduro, Abraham</creatorcontrib><creatorcontrib>Halidou, Tinto</creatorcontrib><creatorcontrib>Gyapong, Margaret</creatorcontrib><creatorcontrib>Sie, Ali</creatorcontrib><creatorcontrib>Macete, Eusebio</creatorcontrib><creatorcontrib>Abdulla, Salim</creatorcontrib><creatorcontrib>Owusu-Agyei, Seth</creatorcontrib><creatorcontrib>Mulokozi, Abdunoor</creatorcontrib><creatorcontrib>Adjei, Alex</creatorcontrib><creatorcontrib>Sevene, Esperanca</creatorcontrib><creatorcontrib>Compaoré, Guillaume</creatorcontrib><creatorcontrib>Valea, Innocent</creatorcontrib><creatorcontrib>Osei, Isaac</creatorcontrib><creatorcontrib>Yawson, Abena</creatorcontrib><creatorcontrib>Adjuik, Martin</creatorcontrib><creatorcontrib>Akparibo, Raymond</creatorcontrib><creatorcontrib>Ogutu, Bernhards</creatorcontrib><creatorcontrib>Upunda, Gabriel Leonard</creatorcontrib><creatorcontrib>Smith, Peter</creatorcontrib><creatorcontrib>Binka, Fred</creatorcontrib><title>Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania</title><title>Malaria journal</title><addtitle>Malar J</addtitle><description>The World Health Organization recommends artemisinin-based combination (ACT) for the treatment of uncomplicated malaria. Post-licensure safety data on newly registered ACT is critical for evaluating their risk/benefit profile in malaria endemic countries. The clinical safety of the newly registered combination, Eurartesim®, following its introduction into the public health system in four African countries was assessed.
This was a prospective, observational, open-label, non-comparative, longitudinal, multi-centre study using cohort event monitoring. Patients with confirmed malaria had their first dose observed and instructed on how to take the second and the third doses at home. Patients were contacted on day 5 ± 2 to assess adherence and adverse events (AEs). Spontaneous reporting of AEs was continued till day 28. A nested cohort who completed full treatment course had repeated electrocardiogram (ECG) measurements to assess effect on QTc interval.
A total of 10,925 uncomplicated malaria patients were treated with Eurartesim®. Most patients,95% (10,359/10,925), did not report any adverse event following at least one dose of Eurartesim®. A total of 797 adverse events were reported. The most frequently reported, by system organ classification, were infections and infestations (3. 24%) and gastrointestinal disorders (1. 37%). In the nested cohort, no patient had QTcF > 500 ms prior to day 3 pre-dose 3. Three patients had QTcF > 500 ms (509 ms, 501 ms, 538 ms) three to four hours after intake of the last dose. All the QTcF values in the three patients had returned to <500 ms at the next scheduled ECG on day 7 (470 ms, 442 ms, 411 ms). On day 3 pre- and post-dose 3, 70 and 89 patients, respectively, had a QTcF increase of ≥ 60 ms compared to their baseline, but returned to nearly baseline values on day 7.
Eurartesim® single course treatment for uncomplicated falciparum malaria is well-tolerated. QT interval prolongation above 500 ms may occur at a rate of three per 1,002 patients after the third dose with no association of any clinical symptoms. QT interval prolongation above 60 ms was detected in less than 10% of the patients without any clinical abnormalities.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Africa</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antimalarials - administration & dosage</subject><subject>Antimalarials - adverse effects</subject><subject>Artemisinins - administration & dosage</subject><subject>Artemisinins - adverse effects</subject><subject>Care and treatment</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cohort Studies</subject><subject>Comparative analysis</subject><subject>Control</subject><subject>Drug Combinations</subject><subject>Drug therapy</subject><subject>Drug-Related Side Effects and Adverse Reactions - epidemiology</subject><subject>Drug-Related Side Effects and Adverse Reactions - pathology</subject><subject>Female</subject><subject>Gastrointestinal diseases</subject><subject>Health aspects</subject><subject>Health Facilities</subject><subject>Heart Conduction System - drug effects</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Longitudinal Studies</subject><subject>Malaria</subject><subject>Malaria - drug therapy</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Quinolines - administration & dosage</subject><subject>Quinolines - adverse effects</subject><subject>Safety and security measures</subject><subject>Young Adult</subject><issn>1475-2875</issn><issn>1475-2875</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptUsFu1DAQjRCIlsIHcEGWuIC0aeMkdrIXpFK1BakIDuVsTexxY8jaqe2s2H4UH8Hv8BM4u1BtJeSDrZn33oxnXpa9pMUxpS0_CbRcVjwvKMsLzut8-Sg7pHXD8rJt2OO990H2LIRvRUGbtimfZgcla1uWzmH2-4t3YUQZzRqJ6wL6NUTjLAwkxEltSHQE1zBMEJHEHokcjDVyToPGuCFOb8Pa_ECVKxeQgI-4MiHBbN5BQEWkW3XGbnXJ-eRnQDCrXz_JG2X6jfJuj3IymhE93E7G4tsFMZaMUzcYSXqEIfZEgzSDiQbDnHs_-e9JmVxAcAvyyd1BqnQ74YJc9mBhQcAqcg32DqyB59kTDUPAF3_vo-zrxfn12Yf86vPlx7PTq1zWnMe8qxpW4BIVpDHpupZM4ZK1wNuq6RSXleYcUpxKKDvGqlKmpGRaNyVqypbVUfZup5s6X6GSaKOHQYzerMBvhAMjHmas6cWNW4u6LljLmyTweidwAwMKY7VLMJkGJMUpq9NWq3Zb5vg_qHRUmqV0FrVJ8QcEuiPItPPgUd-3RAsxG0rsDCWSocRsKDFzXu3_5Z7xz0HVH4mVzvo</recordid><startdate>20150415</startdate><enddate>20150415</enddate><creator>Baiden, Rita</creator><creator>Oduro, Abraham</creator><creator>Halidou, Tinto</creator><creator>Gyapong, Margaret</creator><creator>Sie, Ali</creator><creator>Macete, Eusebio</creator><creator>Abdulla, Salim</creator><creator>Owusu-Agyei, Seth</creator><creator>Mulokozi, Abdunoor</creator><creator>Adjei, Alex</creator><creator>Sevene, Esperanca</creator><creator>Compaoré, Guillaume</creator><creator>Valea, Innocent</creator><creator>Osei, Isaac</creator><creator>Yawson, Abena</creator><creator>Adjuik, Martin</creator><creator>Akparibo, Raymond</creator><creator>Ogutu, Bernhards</creator><creator>Upunda, Gabriel Leonard</creator><creator>Smith, Peter</creator><creator>Binka, Fred</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20150415</creationdate><title>Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania</title><author>Baiden, Rita ; Oduro, Abraham ; Halidou, Tinto ; Gyapong, Margaret ; Sie, Ali ; Macete, Eusebio ; Abdulla, Salim ; Owusu-Agyei, Seth ; Mulokozi, Abdunoor ; Adjei, Alex ; Sevene, Esperanca ; Compaoré, Guillaume ; Valea, Innocent ; Osei, Isaac ; Yawson, Abena ; Adjuik, Martin ; Akparibo, Raymond ; Ogutu, Bernhards ; Upunda, Gabriel Leonard ; Smith, Peter ; Binka, Fred</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-b3750e9eda258f44c5de958a6837bd6c3f66af441ca2b5532c58ac5ff72ef1593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Africa</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antimalarials - administration & dosage</topic><topic>Antimalarials - adverse effects</topic><topic>Artemisinins - administration & dosage</topic><topic>Artemisinins - adverse effects</topic><topic>Care and treatment</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cohort Studies</topic><topic>Comparative analysis</topic><topic>Control</topic><topic>Drug Combinations</topic><topic>Drug therapy</topic><topic>Drug-Related Side Effects and Adverse Reactions - epidemiology</topic><topic>Drug-Related Side Effects and Adverse Reactions - pathology</topic><topic>Female</topic><topic>Gastrointestinal diseases</topic><topic>Health aspects</topic><topic>Health Facilities</topic><topic>Heart Conduction System - drug effects</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Longitudinal Studies</topic><topic>Malaria</topic><topic>Malaria - drug therapy</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Quinolines - administration & dosage</topic><topic>Quinolines - adverse effects</topic><topic>Safety and security measures</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baiden, Rita</creatorcontrib><creatorcontrib>Oduro, Abraham</creatorcontrib><creatorcontrib>Halidou, Tinto</creatorcontrib><creatorcontrib>Gyapong, Margaret</creatorcontrib><creatorcontrib>Sie, Ali</creatorcontrib><creatorcontrib>Macete, Eusebio</creatorcontrib><creatorcontrib>Abdulla, Salim</creatorcontrib><creatorcontrib>Owusu-Agyei, Seth</creatorcontrib><creatorcontrib>Mulokozi, Abdunoor</creatorcontrib><creatorcontrib>Adjei, Alex</creatorcontrib><creatorcontrib>Sevene, Esperanca</creatorcontrib><creatorcontrib>Compaoré, Guillaume</creatorcontrib><creatorcontrib>Valea, Innocent</creatorcontrib><creatorcontrib>Osei, Isaac</creatorcontrib><creatorcontrib>Yawson, Abena</creatorcontrib><creatorcontrib>Adjuik, Martin</creatorcontrib><creatorcontrib>Akparibo, Raymond</creatorcontrib><creatorcontrib>Ogutu, Bernhards</creatorcontrib><creatorcontrib>Upunda, Gabriel Leonard</creatorcontrib><creatorcontrib>Smith, Peter</creatorcontrib><creatorcontrib>Binka, Fred</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Malaria journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baiden, Rita</au><au>Oduro, Abraham</au><au>Halidou, Tinto</au><au>Gyapong, Margaret</au><au>Sie, Ali</au><au>Macete, Eusebio</au><au>Abdulla, Salim</au><au>Owusu-Agyei, Seth</au><au>Mulokozi, Abdunoor</au><au>Adjei, Alex</au><au>Sevene, Esperanca</au><au>Compaoré, Guillaume</au><au>Valea, Innocent</au><au>Osei, Isaac</au><au>Yawson, Abena</au><au>Adjuik, Martin</au><au>Akparibo, Raymond</au><au>Ogutu, Bernhards</au><au>Upunda, Gabriel Leonard</au><au>Smith, Peter</au><au>Binka, Fred</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania</atitle><jtitle>Malaria journal</jtitle><addtitle>Malar J</addtitle><date>2015-04-15</date><risdate>2015</risdate><volume>14</volume><issue>1</issue><spage>160</spage><pages>160-</pages><artnum>160</artnum><issn>1475-2875</issn><eissn>1475-2875</eissn><abstract>The World Health Organization recommends artemisinin-based combination (ACT) for the treatment of uncomplicated malaria. Post-licensure safety data on newly registered ACT is critical for evaluating their risk/benefit profile in malaria endemic countries. The clinical safety of the newly registered combination, Eurartesim®, following its introduction into the public health system in four African countries was assessed.
This was a prospective, observational, open-label, non-comparative, longitudinal, multi-centre study using cohort event monitoring. Patients with confirmed malaria had their first dose observed and instructed on how to take the second and the third doses at home. Patients were contacted on day 5 ± 2 to assess adherence and adverse events (AEs). Spontaneous reporting of AEs was continued till day 28. A nested cohort who completed full treatment course had repeated electrocardiogram (ECG) measurements to assess effect on QTc interval.
A total of 10,925 uncomplicated malaria patients were treated with Eurartesim®. Most patients,95% (10,359/10,925), did not report any adverse event following at least one dose of Eurartesim®. A total of 797 adverse events were reported. The most frequently reported, by system organ classification, were infections and infestations (3. 24%) and gastrointestinal disorders (1. 37%). In the nested cohort, no patient had QTcF > 500 ms prior to day 3 pre-dose 3. Three patients had QTcF > 500 ms (509 ms, 501 ms, 538 ms) three to four hours after intake of the last dose. All the QTcF values in the three patients had returned to <500 ms at the next scheduled ECG on day 7 (470 ms, 442 ms, 411 ms). On day 3 pre- and post-dose 3, 70 and 89 patients, respectively, had a QTcF increase of ≥ 60 ms compared to their baseline, but returned to nearly baseline values on day 7.
Eurartesim® single course treatment for uncomplicated falciparum malaria is well-tolerated. QT interval prolongation above 500 ms may occur at a rate of three per 1,002 patients after the third dose with no association of any clinical symptoms. QT interval prolongation above 60 ms was detected in less than 10% of the patients without any clinical abnormalities.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>25885858</pmid><doi>10.1186/s12936-015-0664-9</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1475-2875 |
| ispartof | Malaria journal, 2015-04, Vol.14 (1), p.160, Article 160 |
| issn | 1475-2875 1475-2875 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4405867 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Springer Nature OA Free Journals; Springer Nature - Complete Springer Journals; PubMed Central |
| subjects | Adolescent Adult Africa Aged Aged, 80 and over Antimalarials - administration & dosage Antimalarials - adverse effects Artemisinins - administration & dosage Artemisinins - adverse effects Care and treatment Child Child, Preschool Cohort Studies Comparative analysis Control Drug Combinations Drug therapy Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - pathology Female Gastrointestinal diseases Health aspects Health Facilities Heart Conduction System - drug effects Humans Infant Infant, Newborn Longitudinal Studies Malaria Malaria - drug therapy Male Medical research Medicine, Experimental Middle Aged Prospective Studies Quinolines - administration & dosage Quinolines - adverse effects Safety and security measures Young Adult |
| title | Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A12%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospective%20observational%20study%20to%20evaluate%20the%20clinical%20safety%20of%20the%20fixed-dose%20artemisinin-based%20combination%20Eurartesim%C2%AE%20(dihydroartemisinin/piperaquine),%20in%20public%20health%20facilities%20in%20Burkina%20Faso,%20Mozambique,%20Ghana,%20and%20Tanzania&rft.jtitle=Malaria%20journal&rft.au=Baiden,%20Rita&rft.date=2015-04-15&rft.volume=14&rft.issue=1&rft.spage=160&rft.pages=160-&rft.artnum=160&rft.issn=1475-2875&rft.eissn=1475-2875&rft_id=info:doi/10.1186/s12936-015-0664-9&rft_dat=%3Cgale_pubme%3EA541473859%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25885858&rft_galeid=A541473859&rfr_iscdi=true |